Pvg Asset Management Corp Outlook Therapeutics, Inc. Transaction History

Pvg Asset Management Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	BUY	$0.2 - $1.78 $3,471 - $30,891	17,355 Added 42.07%	58,610 $12,000
Q2 2023 Jul 31, 2023	SELL	$1.02 - $1.89 $1,035 - $1,918	-1,015 Reduced 2.4%	41,255 $71,000
Q1 2023 Jul 24, 2023	BUY	$1.0 - $1.35 $25,815 - $34,850	25,815 Added 156.88%	42,270 $46,000
Q3 2022 Oct 13, 2022	BUY	$1.02 - $1.26 $3,294 - $4,069	3,230 Added 24.42%	16,455 $0
Q4 2021 Feb 02, 2022	BUY	$1.27 - $2.23 $16,795 - $29,491	13,225 New	13,225 $17,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Pvg Asset Management Corp with notifications on news.